Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97(12):2972–7.
Article
Google Scholar
Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17):3608–17.
Article
Google Scholar
Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983;52(12):2349–54.
Article
CAS
Google Scholar
Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J. 1988;81(9):1109–12.
Article
CAS
Google Scholar
Heitz F, Harter P, Lueck H-J, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer. 2009;45(16):2792–8.
Article
CAS
Google Scholar
Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43(4):795–803.
Article
CAS
Google Scholar
Ranjan T, Abrey LE. Current management of metastatic brain disease. Neurotherapeutics. 2009;6(3):598–603.
Article
CAS
Google Scholar
Lassman AB, Abrey LE, Shah GD, Shah GG, Panageas KS, Begemann M, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neuro-Oncol. 2006;78(3):255–60.
Article
CAS
Google Scholar
Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16(4):1561–7.
Article
CAS
Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
Article
CAS
Google Scholar
Bowman KM, Kumthekar P. Medical management of brain metastases and leptomeningeal disease in patients with breast carcinoma. Future Oncol. 2018;14(4):391–407.
Article
CAS
Google Scholar
Cheng X, Hung M-C. Breast cancer brain metastases. Cancer Metastasis Rev. 2007;26(3–4):635–43.
Article
Google Scholar
Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist. 2007;12(7):884–98.
Article
CAS
Google Scholar
Peacock KH, Lesser GJ. Current therapeutic approaches in patients with brain metastases. Curr Treat Options in Oncol. 2006;7(6):479–89.
Article
Google Scholar
Lee Y-C, Hsieh C-C, Chuang J-P, Li C-Y. The necessity of intrathecal chemotherapy for the treatment of breast cancer patients with leptomeningeal metastasis: a systematic review and pooled analysis. Curr Probl Cancer. 2017;41(5):355–70.
Article
Google Scholar
Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neuro-Oncol. 2007;85(3):311–7.
Article
CAS
Google Scholar
Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer. 2009;100(6):894–900.
Article
CAS
Google Scholar
Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, et al. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer. 2012;106(1):25–31.
Article
CAS
Google Scholar
Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler H-J, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452–9.
Article
CAS
Google Scholar
Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–65.
Article
CAS
Google Scholar
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–83.
Article
CAS
Google Scholar
Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71.
Article
CAS
Google Scholar